Valuation: Avacta Group Plc

Market Cap 320M 428M 382M 353M 603M 40.42B 610M 4.24B 1.66B 21.25B 1.61B 1.57B 67.71B P/E 2026 *
-10.8x
P/E 2027 * -11.8x
Enterprise Value 317M 424M 378M 350M 597M 40.03B 604M 4.2B 1.65B 21.04B 1.59B 1.56B 67.05B EV / Sales 2026 *
115x
EV / Sales 2027 * 41.8x
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day-3.81%
1 week+3.46%
Current month-8.75%
1 month-15.77%
3 months-2.67%
6 months-14.68%
Current year+13.28%
1 week 62.55
Extreme 62.55
70
1 month 62
Extreme 62
79
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
152
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 2024-03-31
Director of Finance/CFO 51 2025-01-21
Chief Tech/Sci/R&D Officer - 2026-02-08
Director TitleAgeSince
Director/Board Member 71 2021-08-16
Director/Board Member 56 2022-03-17
Director/Board Member 59 2025-05-27
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/24 Sell

Chief Financial Officer

500,000 0.1393%
9/2/24 Free

Chief Executive Officer

3,600,000 1.0027%
9/2/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+3.46%+1.08%-49.46% 445M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+6.53%+11.68%+87.32% 52.92B
+0.82%+5.41%+8.05%+73.53% 54.82B
+3.28%+5.58%+26.51%+50.05% 44.09B
+0.51%+9.95%+22.40%+133.92% 43.72B
-1.15%+0.39%+263.21%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-0.68%+37.15%+7.16% 26.17B
+0.69%+5.60%+36.60%+26.94% 23.37B
Average -0.13%+5.34%+47.28%+105.75% 38.79B
Weighted average by Cap. +0.31%+4.99%+51.44%+127.57%

Financials

2026 *2027 *
Net sales 2.75M 3.68M 3.28M 3.04M 5.18M 348M 5.24M 36.43M 14.3M 183M 13.82M 13.53M 582M 8.1M 10.85M 9.67M 8.95M 15.26M 1.02B 15.44M 107M 42.11M 538M 40.7M 39.85M 1.71B
Net income -28.92M -38.73M -34.51M -31.95M -54.48M -3.65B -55.13M -383M -150M -1.92B -145M -142M -6.12B -23.64M -31.66M -28.21M -26.12M -44.53M -2.99B -45.06M -313M -123M -1.57B -119M -116M -5B
Net Debt -3.12M -4.18M -3.72M -3.44M -5.87M -394M -5.94M -41.3M -16.21M -207M -15.66M -15.34M -660M 18.36M 24.59M 21.92M 20.29M 34.6M 2.32B 35.01M 243M 95.46M 1.22B 92.26M 90.34M 3.89B
Projected Income Statement - Annual - Avacta Group Plc
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
26-10-21 GBX 65.70 -3.81% 1,443,970
26-10-20 GBX 68.30 +0.44% 1,979,352
26-10-19 GBX 68.00 +1.49% 1,623,292
26-10-16 GBX 67.00 +3.08% 3,643,200
26-10-15 GBX 65.00 +1.25% 1,435,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Avacta Group Plc
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.6570GBP
Average target price
0.9300GBP
Spread / Average Target
+41.55%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avacta Group Plc
  1. Stock Market
  2. Stocks
  3. AVCT Stock